Microfluidics
expert, Dolomite, is delighted to announce its collaboration with
Clearbridge BioMedics in the development of a novel instrument capable
of detecting and isolating Circulating Tumour Cells (CTCs) from small
quantities of whole, unprocessed blood.
The
innovative ClearCell
TM System can isolate, enumerate and most
importantly retrieve wholly intact and viable CTCs from patient whole
blood. Benefiting a broad range of application areas including molecule
analysis, cancer diagnostics and cancer treatment decisions, this
revolutionary instrument also paves the way for personalised cancer
medication for patients.
Speaking
of this success, Andrew Lovatt, the CEO of Dolomite, says, "We are
excited to be working with an innovative company like Clearbridge
BioMedics. The collaboration is an excellent example of how Dolomite is
able to help start-up companies productize science. By combining the
cutting edge scientific research of Clearbridge BioMedics and National
University of Singapore with the proven track record in product
development of Dolomite, both companies have leveraged their expertise
to gain early traction in the novel field of automated capture of viable
CTCs. We are looking forward to extending our partnership beyond
research tools and into the clinical diagnostic domain."
"We
see microfluidics playing an increasing key role in many Companion
Diagnostics and In-Vitro Diagnostics devices. Dolomite has demonstrated
that they are indeed a leader in this field, and we look forward to
developing our future platform devices and systems together", commented
Johnson Chen, Managing Director of Clearbridge BioMedics.
For
further information on Dolomite's instrument development solutions as
well as the complete portfolio of microfluidic products including chips,
connectors/ interconnects, pumps, valves and custom devices please
visit
www.dolomite-microfluidics.com.
The Dolomite Centre Limited
Established
in 2005 as the world's first Microfluidic Application Centre, Dolomite
focused on working with customers to turn their concepts for
microfluidic applications into reality. Today, Dolomite is the world
leader in solving microfluidic problems. With offices in the UK and US
and distributors throughout the rest of the world, its clients range
from universities developing leading-edge analytical equipment, to
manufacturers of chemical, life sciences and clinical diagnostics
systems.
Dolomite
is pioneering the use of microfluidic devices for small-scale fluid
control and analysis, enabling manufacturers to develop more compact,
cost-effective and powerful instruments. By combining specialist glass,
quartz and ceramic technologies with knowledge of high performance
microfluidics, Dolomite is able to provide solutions for a broad range
of application areas including environmental monitoring, clinical
diagnostics, food and beverage, nuclear, agriculture, petrochemical,
cosmetics, pharmaceuticals and chemicals. Furthermore Dolomite's
in-house micro-fabrication facilities that include clean rooms and
precision glass processing facilities allow to prototype and test all
solutions rapidly which ensures a faster development cycle and reduces
the time to market.
For more information please visit
www.dolomite-microfluidics.com.
Clearbridge BioMedicsClearbridge
BioMedics is a spin-off from the National University of Singapore
(NUS), and an incubatee of Clearbridge Accelerator, a Singapore
Government backed high-technology incubator. Leveraging on a
microfluidic biochip invention, its ClearCell
TM System comprises
patent-pending microfluidic CTChips®, which are able to effectively
detect and isolate wholly-intact CTCs (Circulating Tumour Cells) from
small quantities of whole patient blood samples.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.
For more information on Clearbridge BioMedics' ClearCell
TM System and CTChip®, please visit
www.ClearbridgeBioMedics.com